Table III.
Interaction between genotype and dietary mutagen intake in men
| Mutagen | CYP1A2*F | Cases/controls | OR (95% CI)a | Pinteraction | SULT1A1 | Cases/controls | OR (95% CI)a | Pinteraction |
| MeIQx | ||||||||
| ≤44.98 | AC/CC | 72/67 | 1.0 | 0.148 | GG | 51/67 | 1.0 | 0.566 |
| ≤44.98 | AA | 93/100 | 0.9 (0.6–1.4) | GA/AA | 114/100 | 1.4 (0.9–2.2) | ||
| >44.98 | AC/CC | 74/57 | 1.2 (0.7–1.9) | GG | 70/57 | 1.4 (0.8–2.4) | ||
| >44.98 | AA | 74/78 | 0.8 (0.5–1.3) | GA/AA | 78/78 | 1.2 (0.7–1.9) | ||
| Ptrend | 0.753 | 0.450 | ||||||
| DiMeIQx | ||||||||
| ≤2.37 | AC/CC | 80/72 | 1.0 | 0.569 | GG | 53/69 | 1.0 | 0.995 |
| ≤2.37 | AA | 86/107 | 0.8 (0.5–1.2) | GA/AA | 113/110 | 1.2 (0.8–1.9) | ||
| >2.37 | AC/CC | 66/52 | 1.1 (0.7–1.8) | GG | 68/55 | 1.4 (0.8–2.3) | ||
| >2.37 | AA | 81/71 | 0.9 (0.6–1.6) | GA/AA | 79/68 | 1.4 (0.8–2.3) | ||
| Ptrend | 0.938 | 0.319 | ||||||
| PhIP | ||||||||
| ≤162.3 | AC/CC | 70/75 | 1.0 | 0.133 | GG | 62/77 | 1.0 | 0.902 |
| ≤162.3 | AA | 88/105 | 0.9 (0.6–1.4) | GA/AA | 96/103 | 1.1 (0.7–1.7) | ||
| >162.3 | AC/CC | 76/49 | 1.6 (0.9–2.7) | GG | 59/47 | 1.5 (0.9–2.5) | ||
| >162.3 | AA | 79/73 | 1.1 (0.7–1.8) | GA/AA | 96/75 | 1.5 (0.9–2.4) | ||
| Ptrend | 0.436 | 0.071 | ||||||
| BaP | ||||||||
| ≤52.10 | AC/CC | 67/71 | 1.0 | 0.440 | GG | 55/70 | 1.0 | 0.494 |
| ≤52.10 | AA | 77/104 | 0.8 (0.5–1.2) | GA/AA | 89/105 | 1.0 (0.6–1.6) | ||
| >52.10 | AC/CC | 79/53 | 1.5 (0.9–2.4) | GG | 66/54 | 1.4 (0.9–2.4) | ||
| >52.10 | AA | 90/74 | 1.2 (0.8–2.0) | GA/AA | 103/73 | 1.7 (1.0–2.7) | ||
| Ptrend | 0.197 | 0.016 | ||||||
| Mutagenicity | ||||||||
| ≤7141 | AC/CC | 70/71 | 1.0 | 0.169 | GG | 53/69 | 1.0 | 0.917 |
| ≤7141 | AA | 86/99 | 0.9 (0.6–1.4) | GA/AA | 103/101 | 1.2 (0.8–1.9) | ||
| >7141 | AC/CC | 76/53 | 1.3 (0.8–2.2) | GG | 68/55 | 1.4 (0.8–2.4) | ||
| >7141 | AA | 81/79 | 0.9 (0.6–1.5) | GA/AA | 89/77 | 1.3 (0.8–2.2) | ||
| Ptrend | 0.685 | 0.132 | ||||||
| MeIQx | NAT1 | NAT2 | ||||||
| ≤44.98 | Non*10 | 115/115 | 1.0 | 0.005 | R/I | 64/68 | Reference | 0.355 |
| ≤44.98 | Any*10 | 50/52 | 1.0 (0.6–1.6) | S | 101/99 | 1.1 (0.7–1.7) | ||
| >44.98 | Non*10 | 83/96 | 0.8 (0.5–1.2) | R/I | 66/54 | 1.3 (0.7–2.1) | ||
| >44.98 | Any*10 | 65/39 | 1.6 (1.0–2.7) | S | 82/81 | 0.9 (0.6–1.6) | ||
| Ptrend | 0.210 | 0.922 | ||||||
| DiMeIQx | ||||||||
| ≤2.37 | Non*10 | 118/127 | 1.0 | 0.012 | R/I | 64/68 | 1.0 | 0.799 |
| ≤2.37 | Any*10 | 48/52 | 1.0 (0.6–1.7) | S | 102/111 | 0.9 (0.6–1.5) | ||
| >2.37 | Non*10 | 80/84 | 0.9 (0.6–1.4) | R/I | 66/54 | 1.2 (0.7–2.1) | ||
| >2.37 | Any*10 | 67/39 | 1.8 (1.1–3.0) | S | 81/69 | 1.1 (0.7–1.9) | ||
| Ptrend | 0.142 | 0.885 | ||||||
| PhIP | ||||||||
| ≤162.3 | Non*10 | 105/123 | 1.0 | 0.011 | R/I | 62/66 | 1.0 | 0.858 |
| ≤162.3 | Any*10 | 53/57 | 1.1 (0.7–1.7) | S | 96/114 | 0.9 (0.6–1.4) | ||
| >162.3 | Non*10 | 93/88 | 1.1 (0.7–1.7) | R/I | 68/56 | 1.3 (0.7–2.1) | ||
| >162.3 | Any*10 | 62/34 | 2.2 (1.3–3.7) | S | 87/66 | 1.3 (0.8–2.1) | ||
| Ptrend | 0.018 | 0.293 | ||||||
| BaP | ||||||||
| ≤52.10 | Non*10 | 98/117 | 1.0 | 0.004 | R/I | 57/69 | 1.0 | 0.592 |
| ≤52.10 | Any*10 | 46/58 | 0.9 (0.6–1.6) | S | 87/106 | 1.0 (0.6–1.6) | ||
| >52.10 | Non*10 | 100/94 | 1.2 (0.8–1.8) | R/I | 73/53 | 1.7 (1.0–2.8) | ||
| >52.10 | Any*10 | 69/33 | 2.5 (1.5–4.3) | S | 96/74 | 1.5 (0.9–2.4) | ||
| Ptrend | 0.003 | 0.114 | ||||||
| Mutagenicity | ||||||||
| ≤7141 | Non*10 | 105/115 | 1.0 | 0.005 | R/I | 59/64 | 1.0 | 0.592 |
| ≤7141 | Any*10 | 51/55 | 0.9 (0.6–1.6) | S | 97/106 | 1.0 (0.6–1.6) | ||
| >7141 | Non*10 | 93/96 | 0.9 (0.6–1.4) | R/I | 71/58 | 1.3 (0.8–2.2) | ||
| >7141 | Any*10 | 64/36 | 1.9 (1.2–3.2) | S | 86/74 | 1.1 (0.7–1.8) | ||
| Ptrend | 0.045 | 0.510 | ||||||
R/I = rapid/intermediate; S = slow.
a
OR was adjusted for age, family history of cancer, history of diabetes, smoking status and alcohol consumption.